The Medicines Company (ticker: MDCO, exchange: NASDAQ Global Market (.O))
News Release -
6-Jan-2009
The Medicines Company to Participate in the 27th Annual JP Morgan Healthcare ConferencePARSIPPANY, NJ, Jan 06, 2009 (MARKET WIRE via COMTEX News Network) -- The Medicines Company (NASDAQ: MDCO) is scheduled to participate in
the 27th Annual JP Morgan Healthcare Conference on Tuesday, January
13th, at 9am Pacific Time, 12:00pm Eastern Time. A company overview
and outlook will be provided in the presentation.
The session will be webcast with a link available at The Medicines
Company's website: http://www.themedicinescompany.com.
MDCO-G
About The Medicines Company
The Medicines Company (NASDAQ: MDCO) is focused on advancing the
treatment of critical care patients through the delivery of
innovative, cost-effective medicines to the worldwide hospital
marketplace. The Company markets Angiomax(R) (bivalirudin) in the
United States and other countries for use in patients undergoing
coronary angioplasty, and Cleviprex(R) (clevidipine butyrate)
injectable emulsion in the United States for the reduction of blood
pressure when oral therapy is not feasible or not desirable. The
Company also has an investigational antiplatelet agent, cangrelor, in
late-stage development and a serine protease inhibitor, CU-2010, in
early-stage development. The Company's website is
www.themedicinescompany.com.
Contact:
Robyn Brown
Vice President, Investor Relations
The Medicines Company
973-656-1616
Email Contact
SOURCE: The Medicines Company
http://www2.marketwire.com/mw/emailprcntct?id=42C3D34F194DB0CE
|
The Medicines Company
